Trinity Biotech AI Stock Analysis
Trinity Biotech (TRB0) AI Stock Analysis
Trinity Biotech
(Frankfurt:TRB0)
No summary available
Trinity Biotech (TRB0) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 123.53M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 0.00
- Revenue Growth
- -19.82%
- EPS Growth
- 44.49%
- Country
- Germany
- Employees
- 287
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Trinity Biotech Business Overview & Revenue Model
Company Description
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Afric...
Trinity Biotech Earnings Call Summary
The earnings call reflected a company in transition, with significant improvements in revenue growth and cost reduction measures. However, challenges remain, particularly in the hemoglobin segment and overall net loss, indicating a mixed outlook.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During Trinity Biotech's Q3 2024 earnings call, the company reiterated its guidance for 2024, projecting TrinScreen HIV sales revenue of approximately $10 million and annualized run rate revenues of around $75 million by Q2 2025. The company reported a 3% year-on-year revenue growth, reaching $15.2 million for Q3 2024, primarily driven by a 60% increase in point-of-care revenues due to TrinScreen sales. Operating loss improved by 51% to $2.2 million before restructuring and impairment charges. The company aims to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025 through comprehensive transformation initiatives, including cost reductions and operational efficiencies.
Trinity Biotech Risk Analysis
Trinity Biotech disclosed 1 risk factors in its most recent earnings report. Trinity Biotech reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksTrinity Biotech Peers Comparison
Overall Rating
PRPO60Neutral
INBS54Neutral
BNGO51Neutral
BIAF42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 60Neutral | $39.68M | -36.61 | -7.84% | ― | 21.76% | 22.97% | |
| 54Neutral | $5.84M | -0.26 | -146.09% | ― | 36.55% | 60.09% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 51Neutral | $13.98M | -0.37 | -85.00% | ― | 8.23% | 82.76% | |
| 42Neutral | $4.00M | -0.04 | -331.02% | ― | -18.47% | 87.82% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:TRB0 | Trinity Biotech | 63.60 | 0.00 | 0.00% | |
| PRPO | Precipio | 22.13 | 1.10 | 5.23% | |
| BNGO | Bionano Genomics | 1.00 | -0.50 | -33.33% | |
| INBS | Intelligent Bio Solutions Inc. | 1.76 | -5.16 | -74.57% | |
| BIAF | bioAffinity Technologies, Inc. | 2.20 | -21.50 | -90.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
